Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
795
mi
from 43215
Orlando, FL
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Rowe Neurology Institute
628
mi
from 43215
Lenexa, KA
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Rowe Neurology Institute
628
mi
from 43215
Lenexa, KA
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Parexel International
mi
from 43215
Baltimore, MD
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Parexel International
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
MIND
175
mi
from 43215
Farmington Hills, MI
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
MIND
175
mi
from 43215
Farmington Hills, MI
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Tri-State Mountain Neurology
253
mi
from 43215
Johnson City, TN
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Tri-State Mountain Neurology
253
mi
from 43215
Johnson City, TN
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Network
1000
mi
from 43215
Houston, TX
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Network
1000
mi
from 43215
Houston, TX
Click here to add this to my saved trials
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Integrated Neurology Services
323
mi
from 43215
Alexandria, VA
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Integrated Neurology Services
323
mi
from 43215
Alexandria, VA
Click here to add this to my saved trials
Teriflunomide Male Transmission Study
Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners
Status: Enrolling
Updated:  12/31/1969
Multiple Sclerosis Treatment Center at Griffin Hospital
528
mi
from 43215
Derby, CT
Teriflunomide Male Transmission Study
Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners
Status: Enrolling
Updated: 12/31/1969
Multiple Sclerosis Treatment Center at Griffin Hospital
528
mi
from 43215
Derby, CT
Click here to add this to my saved trials
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Exercise in Multiple Sclerosis
Effects of Exercise on Brain Structure and Function in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
VA Medical Center
621
mi
from 43215
Minneapolis, MN
Exercise in Multiple Sclerosis
Effects of Exercise on Brain Structure and Function in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
VA Medical Center
621
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Alabama
492
mi
from 43215
Birmingham, AL
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Alabama
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
1662
mi
from 43215
Phoenix, AZ
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
USC, Keck School of Medicine
1970
mi
from 43215
Los Angeles, CA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
USC, Keck School of Medicine
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
UC Davis
2042
mi
from 43215
Sacramento, CA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
UC Davis
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Sciences Center
1159
mi
from 43215
Denver, CO
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Sciences Center
1159
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Multiple Sclerosis Treatment Center
528
mi
from 43215
Derby, CT
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Multiple Sclerosis Treatment Center
528
mi
from 43215
Derby, CT
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Shepard Center
436
mi
from 43215
Atlanta, GA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Shepard Center
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Chicago
270
mi
from 43215
Chicago, IL
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Chicago
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Indiana University MS Center
166
mi
from 43215
Indianapolis, IN
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Indiana University MS Center
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Maryland Center for MS
343
mi
from 43215
Baltimore, MD
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Maryland Center for MS
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Wayne State University, Department of Neurology
164
mi
from 43215
Detroit, MI
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Wayne State University, Department of Neurology
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
The Schapiro Center for MS
629
mi
from 43215
Golden Valley, MN
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
The Schapiro Center for MS
629
mi
from 43215
Golden Valley, MN
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Gimbel MS Center at Holy Name Hospital
478
mi
from 43215
Teaneck, NJ
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Gimbel MS Center at Holy Name Hospital
478
mi
from 43215
Teaneck, NJ
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Mexico, MIND Imaging Center
1333
mi
from 43215
Albuquerque, NM
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Mexico, MIND Imaging Center
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Maimonides Medical Center
477
mi
from 43215
Brooklyn, NY
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Maimonides Medical Center
477
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Corinne Goldsmith Dickinson Center for MS
481
mi
from 43215
New York, NY
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Corinne Goldsmith Dickinson Center for MS
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Rochester
354
mi
from 43215
Rochester, NY
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Rochester
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
SUNY Stony Brook
549
mi
from 43215
Stony Brook, NY
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
SUNY Stony Brook
549
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Carolinas HealthCare System
349
mi
from 43215
Charlotte, NC
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Carolinas HealthCare System
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinical Foundation
129
mi
from 43215
Cleveland, OH
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinical Foundation
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Ohio State University MS Center
3
mi
from 43215
Columbus, OH
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Ohio State University MS Center
3
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Science University, MS Center of Oregon, UHS-42
2026
mi
from 43215
Portland, OR
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Science University, MS Center of Oregon, UHS-42
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Physicians
416
mi
from 43215
Philadelphia, PA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Physicians
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Allegheny General Hospital, Allegheny Neurological Associates
163
mi
from 43215
Pittsburgh, PA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Allegheny General Hospital, Allegheny Neurological Associates
163
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
The University of Texas, Houston
995
mi
from 43215
Houston, TX
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
The University of Texas, Houston
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
The Neurological Research center, Inc
546
mi
from 43215
Bennington, VT
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
The Neurological Research center, Inc
546
mi
from 43215
Bennington, VT
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Fletcher Allen Health Care
590
mi
from 43215
Burlington, VT
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Fletcher Allen Health Care
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
MS Hub Medical Group
2006
mi
from 43215
Seattle, WA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
MS Hub Medical Group
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Washington, MS Research Center
2006
mi
from 43215
Seattle, WA
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Washington, MS Research Center
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Foothills Medical Center
1670
mi
from 43215
Calgary,
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Foothills Medical Center
1670
mi
from 43215
Calgary,
Click here to add this to my saved trials
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Washington University SOM
mi
from 43215
Saint Louis, MO
Study of Oral Fampridine-SR in Multiple Sclerosis
Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Washington University SOM
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1972
mi
from 43215
Los Angeles, CA
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 008
537
mi
from 43215
New Haven, CT
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 008
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1370
344
mi
from 43215
Baltimore, MD
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1370
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 11
163
mi
from 43215
Detroit, MI
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 11
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
1333
mi
from 43215
Albuquerque, NM
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10112
355
mi
from 43215
Rochester, NY
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10112
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10183
416
mi
from 43215
Philadelphia, PA
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10183
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
996
mi
from 43215
Houston, TX
Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
996
mi
from 43215
Houston, TX
Click here to add this to my saved trials